Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7771950 versus tucatinib with trastuzumab and capecitabine in previously treated HER2-positive advanced or metastatic breast cancer
CTR20261931Phase 3Active
- Sponsor
- Roche
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of RO7771950, tucatinib, trastuzumab, capecitabine in breast cancer, sponsored by Roche. Started May 2026; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20261931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261931.